UK-based drug discovery services provider Peakdale Molecular has signed an agreement to extend its research collaboration with biotechnology company Centauri Therapeutics.
Peakdale provides its expertise in synthetic and analytical chemistry to support the continued development of Centauri’s Alphamer technology.
Centauri CEO Dr Mike Westby said: “We have been delighted with the rapid progress made in the development of our Alphamer platform, with Peakdale chemists making a significant contribution to meeting our ambitious and demanding scientific objectives.”
The Alphamer technology is based on programmable immunity, in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens in order to combat an infection.
The chemically synthesised molecules have two distinct parts, one end of which binds a cell-surface target on the pathogen using an aptamer, while the other end has specific epitopes that attach to circulating antibodies.
Alphamers possess the ability to redirect pre-existing antibodies to bacteria in a specific manner that would initiate an immediate antibacterial immune response, thereby clearing the infection.
Peakdale chief operating officer Dr Paul Doyle said: “Centauri is operating in an exciting area, in which expertise within complex synthetic and analytical chemistry is a key component.
“We are delighted that the decades of experience Peakdale has acquired, combined with our partnership approach, has demonstrated the value working with Peakdale can provide.”
Centauri acquired the Alphamer platform after the release of a successful preclinical proof of principle study.
The company has been working in collaboration with Peakdale’s experienced team of chemists in a bid to synthesise and evaluate the optimal linker for each bioconjugated Alphamer or aptamer.